$25.88 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter

Wall Street brokerages expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to announce $25.88 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $25.83 million and the highest is $25.90 million. Oxford Immunotec Global posted sales of $23.71 million in the same quarter last year, which suggests a positive year over year growth rate of 9.2%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full-year sales of $25.88 million for the current fiscal year, with estimates ranging from $103.84 million to $104.70 million. For the next year, analysts forecast that the firm will report sales of $119.34 million per share, with estimates ranging from $117.90 million to $120.66 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Oxford Immunotec Global.

Several research firms recently issued reports on OXFD. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the company a “buy” rating in a research note on Monday, December 18th. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research downgraded Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Robert W. Baird restated a “buy” rating and set a $20.00 price target on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. Finally, ValuEngine cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.75.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the sale, the director now directly owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.11% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Redmile Group LLC boosted its position in shares of Oxford Immunotec Global by 7.5% in the 2nd quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after purchasing an additional 151,100 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in shares of Oxford Immunotec Global by 44.0% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock worth $22,773,000 after purchasing an additional 413,904 shares in the last quarter. RTW Investments LP boosted its position in shares of Oxford Immunotec Global by 21.9% in the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock worth $17,344,000 after purchasing an additional 185,453 shares in the last quarter. Wasatch Advisors Inc. boosted its position in shares of Oxford Immunotec Global by 35.5% in the 3rd quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock worth $9,646,000 after purchasing an additional 150,343 shares in the last quarter. Finally, Cortina Asset Management LLC boosted its position in shares of Oxford Immunotec Global by 12.8% in the 3rd quarter. Cortina Asset Management LLC now owns 563,290 shares of the company’s stock worth $9,463,000 after purchasing an additional 63,765 shares in the last quarter. 89.35% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Oxford Immunotec Global (OXFD) opened at $14.06 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30. Oxford Immunotec Global has a 52-week low of $12.19 and a 52-week high of $19.51. The stock has a market capitalization of $357.37, a price-to-earnings ratio of -6.96 and a beta of -0.09.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/06/25-88-million-in-sales-expected-for-oxford-immunotec-global-plc-oxfd-this-quarter.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply